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fd. Note - This overview was originally presented at the
International Symposium on Clinical Disorders of Bone
and Mineral Metabolism, May 9-13,1983. The following
list indicates the presentations given in this session at the
Symposium and the contents ofthe corresponding
chapter in the Proceedings of the Symposium published by
Excerpta Medica. The numbers in parentheses refer to
pages in this volume. Complete information about the
contents ofthe Proceedings can be found at the back of
this issue.

Cell biology o f t h e parathyroid gland and its relationship
to hyperplasia. L.M. Sherwood, J. Russell, and G. Bhargava (131)
The two-hit theory of neoplasia: Implications for the
pathogenesis of hyperparathyroidism. C.E.Jackson (135)
The interaction between abnormal cellular proliferation
and secretion in primary hyperparathyroidism. E.M.
Brown, M.S. LeBoff, D. Shoback, and R.E. Wilson (139)

REGULATION OF PTH BIOSYNTHESIS AND SECRETION

W i t h the advent of routine screening procedures for
serum calcium, primary hyperparathyroidism has been
recognized as an extraordinarily c o m m o n disorder,
increasing in frequency in the elderly. Secondary
hyperparathyroidism, which is associated w i t h chronic
renal failure, may also occur in patients w i t h malabsorption, vitamin D deficiency, and other causes of low
serum calcium. The papers in this session dealt with
various aspects of normal parathyroid cell biology and
biochemistry as well as abnormalities identified in
hyperplastic or adenomatous glands. A l t h o u g h recognition of the clinical disorders is relatively straightforward and diagnosis by radioimmunoassay relatively
simple (despite the caveats of PTH radioimmunoassay),
much needs to be learned about normal and abnormal
control mechanisms, as well as pathogenetic factors,
particularly in primary hyperparathyroidism.
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ing at the biosynthetic level, but our laboratory has provided the first evidence for a direct effect of calicum on
levels of pre-pro PTH mRNA in the parathyroid cell (J
Clin Invest, in press). A great deal of new information
needs to be obtained, but the sophisticated tools of
molecular biology are readily available, and these issues
should be understood more clearly in the near future. A

During the past two decades, PTH from humans, the
cow, and a number of other species has been purified
and sequenced, and the critical features of peptide structure necessary for biologic activity determined (Fig. 1).
The biosynthesis of hormone and its precursor forms has
been elaborated, the precursor has been synthesized in
cell-free systems, and the complete sequence of DNA
coding for hormonal mRNA has been identified. These
issues were reviewed in the discussion by Sherwood and
colleagues (pp. 131 ff.). Extraordinarily little information
is available at present about control mechanisms operat-
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paucity of data exists on the regulation of biosynthetic
mechanisms in normal glands, but no data exist at all on
these issues in adenomatous or hyperplastic glands. That
should also be forthcoming.
The regulation of hormone secretion has been explored
extensively in vitro and in vivo by many workers, including Sherwood, Brown, C o h n , Fischer, Mayer, Aurbach,
Potts, Williams, and others. Brown, et al (pp. 139 ff.)
reviewed the use of isolated parathyroid cells to study
aspects of normal and abnormal secretion; they discussed the definition of parameters of secretion such as
maximal secretory rate, set point, slope o f t h e curve at its
midpoint, and minimal secretory rate. It has been well
documented that minimal secretion occurs both in vivo
and in vitro despite calcium concentrations higher than
normal. This factor contributes to the overall secretory
rate in hyperparathyroidism. Increases in set point (the
calcium level at which 50% suppression of PTH secretion
occurs) in some patients with primary hyperparathyroidism is considered a significant factor in the oversecretion
of h o r m o n e . Both set point and minimal secretory rate
are related to cell number. Agents other than low calcium have been identified as secretogogues for PTH,
including beta agonists, dopamine, histamine, secretin,
and prostaglandins. These appear to act through adenylate cyclase and cyclic AMP, but their physiologic importance has not been defined. Likewise, failure to d e m o n strate convincingly that beta blockers or histamine
receptor antagonists are useful in controlling secretion
of hormone on a chronic basis lessens the potential
therapeutic significance of these agents. Mechanisms
are being defined by which low calcium, other divalent
cations such as magnesium, and other agonists which
activate cyclic A M P stimulate PTH secretion. Data on the
interaction of calcium and other regulators in abnormal
parathyroid glands are incomplete.
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Finally, little information is available about the regulation of cell growth and number, either benign (hyperplasia, adenoma) or malignant (carcinoma). Jackson (pp.
135 ff.) described an interesting means of assessing
pathogenesis through the measurement of glucose 6phosphate hydrogenase in parathyroid adenomas. A l though these fascinating studies suggest that adenomas
are polyclonal and imply that stimulatory factors may
lead to primary hyperplasia, the nature of such factors is
very obscure. The only known stimulus to parathyroid
hyperplasia is a low serum calcium. Hyperplasia, readily
produced in animals maintained on a low calcium diet,
occurs in patients with renal failure and other disorders
such as malabsorption or vitamin D deficiency in which
the serum calcium is low. These patients have low or
normal serum calcium unless marked hyperplasia o f t h e
glands causes a hypercalcemic state. This unusual occurrence has been described in both chronic renal failure
and in malabsorption, but the hypercalcemia that occurs
in the postrenal transplant state is much more c o m m o n .
In these individuals, who have developed marked hypertrophy and hyperplasia of their glands secondary to
hypocalcemia and vitamin D deficiency and have resistance to PTH action, renal function is corrected by transplantation. With the loss of resistance to PTH action and
the restoration of normal vitamin D metabolism, hypercalcemia commonly results. Usually, the parathyroid
tissue is not functionally autonomous but behaves like
hyperplastic glands. In many of these patients the parathyroid hyperplasia persists for years after renal transplantation. Once developed, the hyperplastic glands
may never regress completely. We know very little about
the factors that generate parathyroid hyperplasia, particularly at the subcellular or membrane level, or about
the factors that might lead to regression.

